Janux Therapeutics JANX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's EBITDA margin?
- Janux Therapeutics (JANX) reported EBITDA margin of -1,128.7% in Q1 2026.
- How has Janux Therapeutics's EBITDA margin changed year-over-year?
- Janux Therapeutics's EBITDA margin increased by 5.5% year-over-year, from -1,194.7% to -1,128.7%.
- What is the long-term trend for Janux Therapeutics's EBITDA margin?
- Over 4 years (2021 to 2025), Janux Therapeutics's EBITDA margin has grown at a 14.6% compound annual growth rate (CAGR), from -902.3% to -1,556.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.